Briacell Therap (NASDAQ:BCTX) Sees Significant Decline in Short Interest

Briacell Therap (NASDAQ:BCTX) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 227,052 shares, a drop of 19.7% from the March 31st total of 282,815 shares. Based on an average daily trading volume, of 120,174 shares, the short-interest ratio is presently 1.9 days. Approximately 3.2% of the company’s shares are short sold.

Briacell Therap Stock Performance

NASDAQ BCTX opened at $4.18 on Friday. Briacell Therap has a one year low of $3.60 and a one year high of $41.30. The company’s 50 day moving average price is $4.12 and its 200 day moving average price is $6.83. The firm has a market capitalization of $30.31 million, a price-to-earnings ratio of -0.18 and a beta of 1.26.

Briacell Therap (NASDAQ:BCTX) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($2.58) EPS for the quarter.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BCTX. Wall Street Zen upgraded shares of Briacell Therap from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Flagship Harbor Advisors LLC acquired a new stake in Briacell Therap (NASDAQ:BCTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned approximately 0.21% of Briacell Therap as of its most recent SEC filing. Hedge funds and other institutional investors own 15.42% of the company’s stock.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.